GLP-1 RA Trial Solutions | Signant Health The evolution of patient-reported outcomes (PROs) in early-phase oncology trials Regulatory guidance and sponsor priorities are converging to incorporate PROs into early-phase oncology trial designs, particularly as they offer critical insights into symptomatic adverse events and patient tolerability, which are vital for optimal dose determination and safety evaluation
Patients were instructed to use high dose vitamin B12 nasal drops (5,000 mcg one nasal drop in each nostril, twice per week)
Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinsons disease (PD): The LIXIPARK trial ( NCT03439943)
Due to its exceptional water-binding capacity, Hyaluronic Acid has become one of the most researched compounds for improving skin moisture, elasticity, and overall appearance while supporting the extracellular matrix